UBS and Citi Go Bullish on Gilead Sciences (GILD)
On January 7, 2026, reports highlighted that analysts are increasingly confident in Gilead Sciences, Inc.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 9,488 | $1,164,557 | -4% | 0.56% |
| 2. | Sivik Global Healthcare Krishen Sud | 25,000 | $3,069 | 0.89% | |
| 3. | Ayrshire Capital Management John Nevin Jr. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | $999,150.00 | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | $430,493.00 | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | $439,955.00 | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | $335,974.40 | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | $158,064.64 | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $135.00 | 115,640 | $15,611,400.00 | 566,698 | 2026-01-23 | Filing | |
| $123.50 | 5,000 | $617,500.00 | 8,920 | 2026-01-20 | Filing | |
| $124.31 | 3,000 | $372,930.00 | 150,503 | 2026-01-15 | Filing | |
| $124.31 | 3,000 | $372,930.00 | 103,221 | 2026-01-15 | Filing | |
| $124.83 | 10,000 | $1,248,272.00 | 566,698 | 2025-12-29 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,138,699 | $630,055,884 | 0.54% | |
| 2. | 4,223,304 | $518,368,332 | 0.17% | |
| 3. | 3,693,602 | $453,352,712 | 0.65% | |
| 4. | 3,269,117 | $401,251,421 | 0.24% | |
| 5. | 1,613,608 | $198,054,246 | 0.43% |
News See All
11 Most Undervalued Blue Chip Stocks to Buy Now
As we enter 2026, U.S. equities are expected to enter a phase marked by several complexities following the outsized gains in 2025.
Morgan Stanley Expects Gilead Sciences (GILD) to Thrive as Biopharma Policy Uncertainties Fade in 2026
Gilead Sciences Inc. (NASDAQ:GILD) is one of the best stocks for the next decade.
Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs
On December 19, Gilead Sciences, Inc. (NASDAQ:GILD) announced an agreement with the US government aimed at lowering drug costs for Americans.
Is Gilead Sciences (GILD) An Affordable Healthcare Stocks to Invest In?
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best affordable healthcare stocks to buy now. Gilead Sciences, Inc.
14 Best Pharma Dividend Stocks to Buy in 2026
For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other developed countries. Branded medicines carry even steeper premiums.
Long-Term Stock Portfolio: 10 Best Stocks for the Next Decade
On December 16, Julian Emanuel, Senior Managing Director at Evercore ISI, shared his outlook on the equity market and the ongoing influence of AI.
10 Best Affordable Healthcare Stocks to Buy Now
According to him, this has been a year where certain areas of healthcare, particularly those related to health spend or real significant turnarounds in business, have performed pretty well, allowing certain...
Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best pharma stocks to invest in. Cantor Fitzgerald analyst Carter Gould maintained a Buy rating on Gilead Sciences, Inc.
11 Best Pharma Stocks to Invest In
CNBC reported on December 1 that the UK and US governments reached a deal on drug pricing.
Hedge Fund Resource Center Billionaire Hedge Funds
